Beam Therapeutics Inc.
BEAM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $64 | $378 | $61 | $52 |
| % Growth | -83.2% | 520% | 17.5% | – |
| Cost of Goods Sold | $368 | $0 | $312 | $232 |
| Gross Profit | -$304 | $378 | -$251 | -$180 |
| % Margin | -478.7% | 100% | -411.5% | -347.8% |
| R&D Expenses | $368 | $437 | $312 | $387 |
| G&A Expenses | $112 | $117 | $88 | $57 |
| SG&A Expenses | $112 | $117 | $88 | $57 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$368 | $0 | -$312 | -$232 |
| Operating Expenses | $112 | $554 | $88 | $212 |
| Operating Income | -$416 | -$176 | -$338 | -$392 |
| % Margin | -654.3% | -46.7% | -555.6% | -757% |
| Other Income/Exp. Net | $39 | $45 | $53 | $22 |
| Pre-Tax Income | -$377 | -$131 | -$286 | -$371 |
| Tax Expense | $0 | $1 | $3 | $0 |
| Net Income | -$377 | -$133 | -$289 | -$371 |
| % Margin | -593.1% | -35.1% | -474.5% | -714.9% |
| EPS | -4.58 | -1.72 | -4.13 | -5.77 |
| % Growth | -166.3% | 58.4% | 28.4% | – |
| EPS Diluted | -4.58 | -1.72 | -4.13 | -5.77 |
| Weighted Avg Shares Out | 82 | 77 | 70 | 64 |
| Weighted Avg Shares Out Dil | 82 | 77 | 70 | 64 |
| Supplemental Information | – | – | – | – |
| Interest Income | $49 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $22 | $30 | $14 | $7 |
| EBITDA | -$394 | -$147 | -$324 | -$230 |
| % Margin | -619.7% | -38.9% | -532.4% | -443.8% |